This inventor holds 1 USPTO granted patent. Top assignee: Olipass Corporation. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Innovations of Sun Hwa Park in Pain Management
Introduction
Sun Hwa Park is an innovative inventor based in Siheung-si, South Korea. He has made significant contributions to the field of pain management through his research and inventions. His work focuses on developing novel therapeutic approaches to treat pain conditions effectively.
Latest Patents
One of Sun Hwa Park's notable patents is the SCN9A antisense pain killer. This invention provides peptide nucleic acid derivatives that target the 3' splice site of exon 4 in the human SCN9A pre-mRNA. The peptide nucleic acid derivatives potently induce SCN9A mRNA splice variant(s) that lack the SCN9A exon 4 in cells. This innovation is useful for safely treating pains or conditions involving Na1.7 activity. Sun Hwa Park holds 1 patent related to this groundbreaking work.
Career Highlights
Sun Hwa Park is associated with Olipass Corporation, where he continues to advance his research in pain management. His work has garnered attention for its potential to revolutionize how pain is treated, providing safer and more effective options for patients.
Collaborations
Sun Hwa Park collaborates with talented individuals in his field, including Shin Chung and Daram Jung. These partnerships enhance the research and development process, leading to innovative solutions in pain management.
Conclusion
Sun Hwa Park's contributions to the field of pain management through his innovative patent demonstrate his commitment to improving therapeutic options for patients. His work is paving the way for future advancements in this critical area of healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile